Impact of Baricitinib on Patients’ Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry
DOI:
https://doi.org/10.2340/actadv.v103.14153Keywords:
atopic dermatitis, baricitinib, Janus kinase inhibitors, Quality of Life, RegistryAbstract
The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials; however, very few real-life studies have been published to date. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) registry was initiated to prospectively determine the long-term impairment caused by chronic inflammatory dermatoses on patients’ lives. The study included 88 patients starting baricitinib for treatment of atopic dermatitis. Clinical evaluation and patient-reported outcomes were recorded at baseline and after 6 and 12 months. After 6 months and 1 year of follow-up, 65 and 47 patients, respectively, were still being treated with baricitinib. Treatment failure was the main reason for discontinuation. Only 1 patient stopped baricitinib because of a side-effect. After 1 year of follow-up, the mean Eczema Area and Severity Index score decreased significantly from 20.7 to 6.4; the percentage of patients with severe atopic dermatitis decreased from 42.9% to 6.5% and a significant improvement in most patient-reported outcomes was noted. There was no difference in terms of efficacy whether or not patients were previously treated with dupilumab. The results remained stable after 6 and 12 months of treatment, which suggests a sustained efficacy of the treatment in patients who initially responded well.
Downloads
References
Richard MA, Corgibet F, Beylot-Barry M, Barbaud A, Bodemer C, Chaussade V, et al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the "Objectifs Peau" study. J Eur Acad Dermatol Venereol 2018; 32: 1967-1971.
https://doi.org/10.1111/jdv.14959 DOI: https://doi.org/10.1111/jdv.14959
Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy 2018; 73: 1284-1293.
https://doi.org/10.1111/all.13401 DOI: https://doi.org/10.1111/all.13401
Simpson EL, Bieber T, Eckert L, Wu R, Ardeleanu M, Graham NM, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol 2016; 74: 491-498.
https://doi.org/10.1016/j.jaad.2015.10.043 DOI: https://doi.org/10.1016/j.jaad.2015.10.043
Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. The burden of atopic dermatitis in US adults: health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol 2018; 78: 54-61.e1.
https://doi.org/10.1016/j.jaad.2017.08.002 DOI: https://doi.org/10.1016/j.jaad.2017.08.002
Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol 2020; 183: 242-255.
https://doi.org/10.1111/bjd.18898 DOI: https://doi.org/10.1111/bjd.18898
Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol 2020; 156: 1333-1343.
https://doi.org/10.1001/jamadermatol.2020.3260 DOI: https://doi.org/10.1001/jamadermatol.2020.3260
Silverberg JI, Simpson EL, Wollenberg A, Bissonnette R, Kabashima K, DeLozier AM, et al. Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials. JAMA Dermatol 2021; 157: 691-699.
https://doi.org/10.1001/jamadermatol.2021.1273 DOI: https://doi.org/10.1001/jamadermatol.2021.1273
Bieber T, Katoh N, Simpson EL, de Bruin-Weller M, Thaçi D, Torrelo A, et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J Dermatolog Treat 2023; 34: 2161812.
https://doi.org/10.1080/09546634.2022.2161812
Reich K, Simpson E, Wollenberg A, Bissonnette R, Abe M, Cardillo T, et al. Efficacy of down titration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3. Br J Dermatol 2023; 188: 208-217.
https://doi.org/10.1093/bjd/ljac057 DOI: https://doi.org/10.1093/bjd/ljac057
Hagino T, Saeki H, Fujimoto E, Kanda N. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol 2023; 50: 869-879.
https://doi.org/10.1111/1346-8138.16763 DOI: https://doi.org/10.1111/1346-8138.16763
Vittrup I, Elberling J, Skov L, Ibler KS, Jemec GBE, Mortz CG, et al. Short-term real-world experience with baricitinib treatment in Danish adults with moderate-severe atopic dermatitis. J Eur Acad Dermatol Venereol 2023; 37: e543-e546.
https://doi.org/10.1111/jdv.18804 DOI: https://doi.org/10.1111/jdv.18804
Uchiyama A, Fujiwara C, Inoue Y, Motegi SI. Real-world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: a single-center retrospective study. J Dermatol 2022; 49: 469-471.
https://doi.org/10.1111/1346-8138.16350 DOI: https://doi.org/10.1111/1346-8138.16350
Rogner D, Biedermann T, Lauffer F. Treatment of atopic dermatitis with baricitinib: first real-life experience. Acta Derm Venereol 2022; 102: adv00677.
https://doi.org/10.2340/actadv.v102.1088 DOI: https://doi.org/10.2340/actadv.v102.1088
Boesjes CM, Kamphuis E, Zuithoff NPA, Bakker DS, Loman L, Spekhorst LS, et al. Daily practice experience of baricitinib treatment for patients with difficult-to-treat atopic dermatitis: results from the BioDay Registry. Acta Derm Venereol 2022; 102: adv00820.
https://doi.org/10.2340/actadv.v102.3978 DOI: https://doi.org/10.2340/actadv.v102.3978
Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol 2015; 172: 1353-1357.
https://doi.org/10.1111/bjd.13662 DOI: https://doi.org/10.1111/bjd.13662
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
https://doi.org/10.1111/j.1365-2230.1994.tb01167.x DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care 1996; 34: 220-233.
https://doi.org/10.1097/00005650-199603000-00003 DOI: https://doi.org/10.1097/00005650-199603000-00003
Thomas KS, Apfelbacher CA, Chalmers JR, Simpson E, Spuls PI, Gerbens LAA, et al. Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. Br J Dermatol 2021; 185: 139-146.
https://doi.org/10.1111/bjd.19751 DOI: https://doi.org/10.1111/bjd.19751
Commission Nationale de L'informatique et des Libertés. Méthodologie de référence MR-003. [accessed 2023 May 8]. Available from https://www.google.com/search?q=cnil&oq=cnil&aqs=chrome..69i57j0i512l9.1655j0j15&sourceid=chrome&ie=UTF-8.
Sreekantaswamy SA, Tully J, Edelman LS, Supiano MA, Butler D. The underrepresentation of older adults in clinical trials of Janus kinase inhibitors in the treatment of atopic dermatitis. J Am Acad Dermatol 2022; 87: 1174-1176.
https://doi.org/10.1016/j.jaad.2022.02.051 DOI: https://doi.org/10.1016/j.jaad.2022.02.051
Thompson D. Replication of randomized, controlled trials using real-world data: what could go wrong? Value Health 2021; 24: 112-115.
https://doi.org/10.1016/j.jval.2020.09.015 DOI: https://doi.org/10.1016/j.jval.2020.09.015
Bieber T, Katoh N, Simpson EL, de Bruin-Weller M, Thaçi D, Torrelo A, et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J Dermatolog Treat 2023; 34: 2161812.
https://doi.org/10.1080/09546634.2022.2161812 DOI: https://doi.org/10.1080/09546634.2022.2161812
Vanlerberghe J, Dezoteux F, Martin C, Jachiet M, Soria A, Tétart F, et al. Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2023; 88: 900-904.
https://doi.org/10.1016/j.jaad.2022.10.034 DOI: https://doi.org/10.1016/j.jaad.2022.10.034
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Ziad Reguiai, Pierre André Becherel, Jean Luc Perrot, Anne Claire Fougerousse, Edouard Begon, Claire Poreaux, Claire Boulard, Guillaume Chaby, Charlotte Fite, Inès Zaraa, Dominique Lons-Danic, Anne-Laure Liegeon, Josiane Parier, Nathalie Quiles-Tsimaratos, Laurene David, François Maccari
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
